Efficacy of Bariatric Surgery in Type 2 Diabetes Mellitus Remission: the Role of Mini Gastric Bypass/One Anastomosis Gastric Bypass and Sleeve Gastrectomy at 1 Year of Follow-up. A European survey
Language English Country United States Media print
Document type Journal Article
PubMed
26341086
DOI
10.1007/s11695-015-1865-6
PII: 10.1007/s11695-015-1865-6
Knihovny.cz E-resources
- Keywords
- Bariatric surgery, European multicenter survey, MGB/OAGB, Mini gastric bypass/one anastomosis gastric bypass, Remission, SG, Sleeve gastrectomy, T2DM, Type 2 diabetes mellitus,
- MeSH
- Diabetes Mellitus, Type 2 complications surgery MeSH
- Adult MeSH
- Gastrectomy methods MeSH
- Weight Loss MeSH
- Middle Aged MeSH
- Humans MeSH
- Obesity, Morbid complications surgery MeSH
- Follow-Up Studies MeSH
- Retrospective Studies MeSH
- Treatment Outcome MeSH
- Gastric Bypass methods MeSH
- Health Surveys MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
BACKGROUND: A retrospective study was undertaken to define the efficacy of both mini gastric bypass or one anastomosis gastric bypass (MGB/OAGB) and sleeve gastrectomy (SG) in type 2 diabetes mellitus (T2DM) remission in morbidly obese patients (pts). METHODS: Eight European centers were involved in this survey. T2DM was preoperatively diagnosed in 313/3252 pts (9.62%). In 175/313 patients, 55.9% underwent MGB/OAGB, while in 138/313 patients, 44.1% received SG between January 2006 and December 2014. RESULTS: Two hundred six out of 313 (63.7 %) pts reached 1 year of follow-up. The mean body mass index (BMI) for MGB/OAGB pts was 33.1 ± 6.6, and the mean BMI for SG pts was 35.9 ± 5.9 (p < 0.001). Eighty-two out of 96 (85.4%) MGB/OAGB pts vs. 67/110 (60.9%) SG pts are in remission (p < 0.001). No correlation was found in the % change vs. baseline values for hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) in relation to BMI reduction, for both MGB/OAGB or SG (ΔFPG 0.7 and ΔHbA1c 0.4 for MGB/OAGB; ΔFPG 0.7 and ΔHbA1c 0.1 for SG). At multivariate analysis, high baseline HbA1c [odds ratio (OR) = 0.623, 95% confidence interval (CI) 0.419-0.925, p = 0.01], preoperative consumption of insulin or oral antidiabetic agents (OR = 0.256, 95% CI 0.137-0.478, p = <0.001), and T2DM duration >10 years (OR = 0.752, 95% CI 0.512-0.976, p = 0.01) were negative predictors whereas MGB/OAGB resulted as a positive predictor (OR = 3.888, 95% CI 1.654-9.143, p = 0.002) of diabetes remission. CONCLUSIONS: A significant BMI decrease and T2DM remission unrelated from weight loss were recorded for both procedures if compared to baseline values. At univariate and multivariate analyses, MGB/OAGB seems to outperform significantly SG. Four independent variables able to influence T2DM remission at 12 months have been identified.
AORN A Cardarelli Naples Italy
AORN G Garibaldi Catania Italy
Břeclav Hospital Břeclav Czech Republic
Centro Hospitalar de Lisboa Central Lisbon Portugal
Clinica Castelli Bergamo Italy
See more in PubMed
Int J Surg. 2015 Feb;14:28-32 PubMed
J Diabetes. 2011 Dec;3(4):261-4 PubMed
Obes Surg. 2014 Oct;24(10):1749-56 PubMed
Diabetes Care. 2014 Jan;37 Suppl 1:S81-90 PubMed
Diabetes Care. 2013 Jan;36 Suppl 1:S11-66 PubMed
Surg Obes Relat Dis. 2015 Sep-Oct;11(5):991-6 PubMed
Obes Surg. 2014 Sep;24(9):1552-62 PubMed
Surg Obes Relat Dis. 2015 Mar-Apr;11(2):321-6 PubMed
N Engl J Med. 2014 May 22;370(21):2002-13 PubMed
Obes Surg. 2001 Jun;11(3):276-80 PubMed
Lancet Diabetes Endocrinol. 2014 Feb;2(2):152-64 PubMed
Ann Surg. 2004 Jan;239(1):1-11 PubMed
Diabetes Care. 2009 Nov;32(11):2133-5 PubMed
Obes Surg. 2014 Apr;24(4):643-4 PubMed
World J Gastroenterol. 2013 Oct 21;19(39):6590-7 PubMed
Ann Ital Chir. 2011 Jul-Aug;82(4):273-7 PubMed
Surg Endosc. 2015 Sep;29(9):2669-74 PubMed
Int J Surg. 2014;12 Suppl 1:S183-8 PubMed
Diabetes Care. 2013 Aug;36(8):2271-9 PubMed
Surg Obes Relat Dis. 2012 Jul-Aug;8(4):445-9 PubMed
Obes Surg. 2015 Jan;25(1):143-58 PubMed
Ann Surg. 2013 Oct;258(4):628-36; discussion 636-7 PubMed
Obes Surg. 2014 Sep;24(9):1430-5 PubMed
Obes Surg. 2013 Dec;23(12):1994-2003 PubMed
Obes Surg. 2014 Oct;24(10):1617-24 PubMed
Obes Surg. 2014 Feb;24(2):324-33 PubMed
J Obes. 2014;2014:638203 PubMed
J Gastrointest Surg. 2012 Jan;16(1):45-51; discussion 51-2 PubMed
Surg Obes Relat Dis. 2012 Jan-Feb;8(1):8-19 PubMed
JAMA. 2012 Jan 4;307(1):56-65 PubMed
Ann Surg. 1995 Sep;222(3):339-50; discussion 350-2 PubMed
N Engl J Med. 2012 Apr 26;366(17):1577-85 PubMed
Ann Surg. 2015 Mar;261(3):459-67 PubMed
JAMA. 2013 Jun 5;309(21):2250-61 PubMed
Int J Obes (Lond). 2009 Apr;33 Suppl 1:S33-40 PubMed
Obes Rev. 2014 Jul;15(7):555-63 PubMed
Int J Cardiol. 2014 Apr 15;173(1):20-8 PubMed
Ann Surg. 2012 Dec;256(6):1023-9 PubMed
J Am Coll Nutr. 2013;32(2):136-42 PubMed
J Clin Endocrinol Metab. 2013 Nov;98(11):4391-9 PubMed
Obes Surg. 2015 Feb;25(2):199-208 PubMed
Am J Med. 2009 Mar;122(3):248-256.e5 PubMed
Arch Surg. 2011 Feb;146(2):143-8 PubMed
Acta Diabetol. 2015 Oct;52(5):937-42 PubMed
N Engl J Med. 2012 Apr 26;366(17):1567-76 PubMed
Surg Endosc. 2014 Jan;28(1):156-63 PubMed